A patient arrives with a folder. Imaging from the emergency department, a discharge summary that says nothing is broken, six weeks of physical therapy notes, and a question nobody has answered: if nothing is wrong, why is this the same as it was in March?
The honest answer starts with a statement that sounds like a limitation and is actually the entire method.
Your body creates the healing
Repair is performed by your cells, out of your raw material, on your metabolic budget, and it is a formidable process when the conditions permit it. Nothing in a syringe replaces it. What a physician contributes is two things, and it is worth being precise about both, because the difference between them is where most of the disappointment in this field comes from.
- Optimize the biological environment in which the repair has to happen — the systemic inflammatory state, glycemic control, micronutrient status, sleep, nicotine exposure, and the mechanical loading the tissue is receiving.
- Deliver a precise cellular catalyst to the structure that needs it, characterized, placed under imaging guidance, at a point in the healing arc where a catalyst has something to catalyze.
We are the catalyst and the conditions. That is the whole offer — smaller than the promises made elsewhere in regenerative medicine, and the version that survives contact with results.
It also carries a corollary that has to be said before anyone spends money. If the metabolic terrain remains inflamed, even a rigorous, correctly targeted, guideline-compliant biologic intervention will fail. It will fail quietly. The procedure will have been performed correctly, the note will read well, and the patient will conclude that the treatment does not work — when what actually happened is that a repair signal was delivered into a system that could not execute it.
Why an injury makes this more acute, not less
There is a reasonable objection: terrain is a chronic-disease argument, and an injury is an event. Somebody hit your car. You fell off a ladder. What does insulin resistance have to do with a torn ligament?
Three things, and they compound.
The repair demand is sudden and large
Degenerative change accumulates over years and the body meets it with a slow, low-grade repair effort. An injury asks for a burst of coordinated collagen synthesis, angiogenesis and remodeling over weeks. A system with limited reserve can carry the slow demand and fail the sudden one, which is why people are surprised by how badly they recover from something they would have shrugged off ten years earlier.
The injury adds inflammation to whatever was already there
Local post-traumatic inflammation is necessary and self-limiting in a healthy system. Layered on top of a chronic systemic inflammatory state, the two do not simply coexist. The baseline raises the ceiling the acute response has to work against, and the resolution phase — the part that is supposed to switch the process off — is where the failure usually occurs. The biochemistry is set out in Joint Pain and Systemic Inflammation.
The window is short and it does not reopen
Chronic degeneration gives you years to intervene. An injury gives you a defined arc: inflammatory, proliferative, remodeling. What is not corrected during that arc is not correctable later at the same cost. The first twelve weeks are therefore worth more than any other twelve weeks in the whole course, and what happens in them has its own article.
The evidence for this is real and it is also honest about its limits
Two findings are worth holding together, because using only the first would be advocacy.
When the risk factors for rotator cuff tendinopathy were pooled and appraised, what emerged was not a list of mechanical exposures but a metabolic and systemic profile. That is the pattern across musculoskeletal medicine: the tissue that fails is usually failing in a body that made failure likelier.
Then there is the result that cuts the other way. Reanalysed against body mass index, one randomized trial found the association held for microfragmented adipose tissue and vanished for platelet-rich plasma — same patients, same measure, two products, opposite answers. That complicates the simple version of our own argument, and we publish it for exactly that reason. Terrain does not act as a general moral about health. It acts through specific mechanisms on specific products in specific tissues, and the correct response to that is to measure rather than to assume. What gets measured is in The Metabolic Audit.
A confession, because it belongs here
For years the standard way to explain a poor result after an injection was patient factors, stated vaguely and usually as a criticism. The patient did not do the rehabilitation. The patient is deconditioned. That framing is both unkind and analytically lazy, and it produced nothing actionable.
The useful version is that most of what was being called a patient factor is a measurable, modifiable biological state. Hemoglobin A1c is a number. So are hsCRP, 25-hydroxyvitamin D, fasting insulin, and hours of sleep. Once they are numbers they stop being character judgments and start being a plan, which is what hsCRP and inflammation biomarkers covers in detail.
What the published guidance implies without ever saying it
Read the sequencing language in the guideline documents and the same architecture appears. The 2025 ASIPP document will not put regenerative therapy anywhere except downstream of a diagnostic work-up and alongside exercise, physical therapy and lifestyle management. ESSKA-ICRS will not call a scenario appropriate unless conservative care has been attempted in it. The multispecialty guidelines only ever asked about problems that had already persisted.
Those documents are describing, in committee language, a treatment that is one component of a plan. The corollary they leave unstated is the one this practice starts with: a plan has prerequisites, and the prerequisites are biological. A catalyst delivered before there is anything to catalyze, or into an environment that cannot execute the instruction, is spent rather than banked. The timing half of that is worked through in the first twelve weeks.
What this means for the folder on the table
A discharge summary saying nothing is broken has answered one question: nothing requires an operation tonight. It has not established what was injured, what state the repair is in, or what is limiting it. Those are three separate assessments, and the order they are done in decides what the eventual result can be.
An injury is not a claim to be processed or a scan to be reread. It is a repair project running in a specific biological environment, on a schedule, with a ceiling that is being set right now.
Frequently Asked Questions
Why does a regenerative practice want my bloodwork before discussing an injection?
Because the injection is autologous — manufactured from your blood or marrow on the morning of the procedure — and the repair it is meant to catalyze runs on your metabolic budget. Inflammatory load, glycemic control, vitamin D status, sleep and nicotine exposure are manufacturing conditions and site conditions at once, which is the argument made in full in You Cannot Out-Inject a Broken Metabolism.
My injury was not my fault. Why are we talking about my metabolic health?
Fault decides who is responsible for what happened. Terrain decides what can now heal, and the two are entirely separate questions. The mechanism by which a systemic inflammatory state changes a local repair is set out in Metainflammation: Why the Same Injection Heals One Person and Fails Another.
If the terrain is the problem, is an injection pointless?
No — it is conditional. A catalyst delivered into a corrected environment does something a catalyst delivered into an inflamed one cannot, which is why the sequence is terrain, then target, then treatment rather than the reverse. What that evaluation involves is described in What happens during a physician-led Clinical Evaluation.
How is an injury different from ordinary wear and tear?
An injury supplies a date, a mechanism and a moment when a joint's chemistry changed, and it starts a trajectory that is measurable decades later — roughly 12% of symptomatic hip, knee and ankle osteoarthritis in the United States is post-traumatic. That trajectory is the subject of the post-traumatic osteoarthritis clock.
Does this mean you will refuse to treat me if my labs are poor?
It means we will tell you what is limiting the ceiling before you spend anything, and treat the limiting factor first where one exists. Deciding that a procedure does not fit today is a normal clinical outcome here rather than a rejection, as described in When orthobiologics are not the right treatment.
Find out what your recovery is actually limited by
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, your imaging and your metabolic data, and a written terrain roadmap before any procedure is discussed. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Sources
- Brown TD, Johnston RC, Saltzman CL, et al. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma, 2006. PubMed 17106388 doi:10.1097/01.bot.0000246468.80635.ef
- Leong HT, Fu SC, He X, et al. Risk factors for rotator cuff tendinopathy: a systematic review and meta-analysis. J Rehabil Med, 2019. PubMed 31489438 doi:10.2340/16501977-2598
- Baria M, George R, Barker T, et al. Relationship of body mass index on patient-reported outcomes after platelet-rich plasma versus microfragmented adipose tissue for knee osteoarthritis: a secondary analysis of a randomized controlled trial. Am J Phys Med Rehabil, 2024. PubMed 38630921 doi:10.1097/PHM.0000000000002499
- Manchikanti L, Navani R, Navani A, et al. Comprehensive evidence-based guidelines for regenerative therapies in the management of chronic low back pain: 2025 update from the American Society of Interventional Pain Physicians (ASIPP). Pain Physician, 2025. PubMed 41481869
- Kon E, Di Matteo B, Delgado D, et al. Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surg Sports Traumatol Arthrosc, 2024. PubMed 38961773 doi:10.1002/ksa.12320
- D'Souza RS, Her YF, Hussain N, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: a consensus report from a multispecialty working group. J Pain Res, 2024. PubMed 39282657 doi:10.2147/JPR.S480559
- Laver L, Filardo G, Sanchez M, et al. The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1 — blood-derived products (platelet-rich plasma). Knee Surg Sports Traumatol Arthrosc, 2024. PubMed 38436492 doi:10.1002/ksa.12077
- Bensa A, Sangiorgio A, Deabate L, et al. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration — a meta-analysis of randomized controlled trials. Am J Sports Med, 2025. PubMed 39751394 doi:10.1177/03635465241246524